Brand Name
Rukobia
Generic Name
Fostemsavir Tromethamine
View Brand Information FDA approval date: July 02, 2020
Form: Tablet
What is Rukobia (Fostemsavir Tromethamine)?
RUKOBIA, in combination with other antiretroviral, is indicated for the treatment of human immunodeficiency virus type 1 infection in heavily treatment-experienced adults with multidrug-resistant HIV-1 infection failing their current antiretroviral regimen due to resistance, intolerance, or safety considerations. RUKOBIA, a human immunodeficiency virus type 1 gp120-directed attachment inhibitor, in combination with other antiretroviral, is indicated for the treatment of HIV-1 infection in heavily treatment-experienced adults with multidrug-resistant HIV-1 infection failing their current antiretroviral regimen due to resistance, intolerance, or safety considerations. ( 1, 1.
Approved To Treat
Top Global Experts
Save this treatment for later
Not sure about your diagnosis?
Related Clinical Trials
Reducing Systemic Inflammation in People on Antiretroviral Therapy
Summary: This randomized, open-label clinical trial will evaluate whether adding fostemsavir to current antiretroviral therapy can reduce the risk of cardiovascular disease in people with well-controlled HIV. Researchers will compare imaging, clinical and biomarker outcomes between participants who receive fostemsavir in addition to their existing treatment and those who continue with standard care alone.